OPEN CLINICAL TRIALS |
| V. 01/20/2023 |
|
Organ System
|
Type
|
Pre-Stage (Non-Cancer)
|
Stage II - III
|
Locally Advanced or Stage IV
|
|
|
Neoadjuvant
|
Adjuvant
|
≥ 1 st Line Therapy
|
≥ 2 nd Line Therapy
|
|
Gastroenterology
|
Fatty Liver Disease
|
Merck Pre-Cirrhotic
NASHb
(MK-6024)
|
|
|
|
|
|
Colorectal Cancer
|
|
Epigenomicsc
(cfDNA)
|
BESPOKE
Colorectaly
(ctDNA)
|
Mirati KRAS G12Cd (MRTX849 + Cetuximab vs. SOC Chemo)
|
Apollomicsic-MET dysregulation (APL-101 VEBRELTINIB)
|
|
BMS Colorectal MSI-H or dMMRk
(Nivo + Ipilimumab)
|
Janssen GIC2002cc
WT KRAS, BRAF,
MSS (Amivantamab + SOC)
|
|
BeiGene CRC MSI-H or dMMRf
(LBL-007 + Tislelizumab
+/- BEVA + Capecitabine)
|
TAPISTRY Studyr
(Multiple Target Therapy)
|
|
Gastroesophageal Adenocarcinoma
(c-MET overexpression)
|
|
|
|
|
AbbVie Solid Tumors M21-404ff
(ABBV-400)
|
|
Hepatocellular Carcinoma
|
|
|
|
BMS (Relativity-106)m
(NIVO + BEVA +/- RELATIMAB)
|
|
|
Squamous Cell Anal Carcinoma
|
|
|
|
Incyten
(Carboplatin, Placitaxel +/- Retifanlimab (Anti PD-1))
|
|
|
Gynecology
|
Triple Negative Breast Cancer
|
|
|
|
|
AbbVie Solid Tumorsa
(anti-TGFB & PD1)
|
|
Breast Cancer (HR-positive/ HER2-negative)
|
|
|
|
|
Pfizer 489g
(ARV-471 vs. Fulvestrant)
|
|
Breast Cancer, Endometrial Cancer or Ovarian Cancer
|
|
|
|
Pfizer 443o
(PF-07260437)
|
Avalonh
(Maveropepimut-S + Cyclophosphamide)
|
|
Breast Cancer or TNBC (HR-positive/ HER2-negative)
|
|
|
|
|
Pfizer 443o
(PF-07260437)
|
|
TNBC
(B7-H4 expression)
|
|
|
|
|
Pfizer 443o
(PF-07260437)
|
|
MULTIPLE SOLID
TUMORS with specific molecular alternations
|
c-MET
|
|
|
|
|
Apollomics/SPARTAi
(c-MET Inhibitor)
|
|
KRAS G12C
|
|
|
|
|
Mirati Solid Tumorsw
(MRTX849 - KRAS G12C Inhibitor)
|
|
|
|
|
|
HBI-2438j
(HBI-2438)
|
|
ROS1-Fusion, NTRK 1/2/3, ALK-Fusion,
TMB-High Tumors, AKT 1/2/3, HER2,
MDM2-Amplified, PIK3CA-mutated
|
|
|
|
|
TAPISTRY Roche
Solid Tumorsr
(Entrectinib, Alectinib,
Atezolizumab, Ipatasertib, Trastuzumab, Idasanutlin, GDC-0077)
|
|
c-MET overexpression
|
|
|
|
|
AbbVie Solid Tumors M21-404ff
(ABBV -400)
|
|
KRAS or EGFR
mutated tumors
|
|
|
|
|
HBI-2376dd
(HBI-2376)
|
|
Head and Neck
|
HNSCC
|
|
|
|
|
AbbVie Solid Tumorsa
(GARF-TGF-{31 & PD-1)
|
|
Pulmonary
|
NSCLC
(EGFR-mutated)
|
|
|
|
|
Janssen (1001) EGFR-19 deletion or L858R; EGFR Exon 20ins activating; uncommon non-Exon 20ins activating or EGFR mutations/alterationss
(Lazertinib & anti-EGFR/cMET)
|
|
Janssen 3002zEGFR Exon 19del or Exon 21 L858R (Amivantamab, Lazertinib, Pemetrexed, Carboplatin)
|
|
NSCLC
(KRAS G12C mutated)
|
|
|
|
Mirati KRAS G12Cw
(MTX)
|
Mirati KRAS G12Cx
(2-MTX vs. Docetaxel)*Must have received Platinum/ anti- PDL1 previous
|
|
NSCLC
(c-MET mutated)
|
|
|
|
|
Apollomicsi
c-MET Exon 14 (APL-101 VEBRELTINIB)
|
|
NSCLC
(c-MET Overexpression)
|
|
|
|
|
AbbVie Solid Tumors M21-404ff
(ABBV -400)
|
|
NSCLC
(RET-Mutated)
|
|
|
Eli Lillyp
(Selpercatinib)
|
|
|
|
NSCLC
|
DELFI-L201ee
>20
pack-years smoker (Chest CT
+ ctDNA)
|
DELFI-L101l
>20
pack-years smoker (cfDNA)
|
|
|
AbbVie Solid Tumorsa
(GARF-TGF-{31 & PD-1)
|
|
Squamous NSCLC
(c-MET Overexpression)
|
|
|
|
|
AbbVie Solid Tumors M21-404ff
(ABBV -400)
|
|
Non-Squamous NSCLC (c-MET Overexpression)
|
|
|
|
|
|
Extensive-Stage SCLC (SSTR+)
|
|
|
|
RayzeBioaa
(RYZ101+Carboplatin+Etoposide
+Atezolizumab)
|
|
|
Urology
|
Muscle-Invasive Bladder Cancer
|
|
Merck MIBC
(non-surgical candidate)v
(Anti-PDL1 & RTX)
|
|
|
|
Non-Muscle Invasive Bladder Cancer
|
|
|
|
Merck High-Risk NMIBCt
(Pembrolizumab)
|
|
|
Urothelial Cell Carcinoma
|
|
|
|
|
AbbVie Solid Tumorsa
(GARF-TGF- β1 & PD-1)
|
|
Dermatology
|
Basal Cell Carcinoma
|
|
|
|
Regeneronbb
(cemiplimab) Phase IV Observational Study
|
|
|
Melanoma
|
|
|
|
HBI-8000u
(HBI-8000 +/- Nivolumab)
|
|
|
Liquid Malignancies
|
Type
|
Maintenance
|
Treatment Naïve
|
Relapsed or Refractory
|
|
Hematology
(Liquid Tumors)
|
Diffuse Large B-Cell Lymphoma
|
|
|
GENENTECHq
(Glofitamab/ Gemcitabine/Oxaliplatin vs. GROC)
|
|
Waldenström Macroglobulinemia
|
BeiGeneb
Phase IV Observational Study (Zanubrutinib)
|
|
|
REFERENCES
aNCT03821935; bNCT05640102; cNCT04027790; dNCT04793958; eNCT04145115; fNCT04542369; gNCT05654623; hNCT05243524; iNCT03175224; jNCT05485974; kNCT04008030; lNCT04825834; mNCT05337137; nNCT04472429; oNCT05067972; pNCT04819100; qNCT04408638; rNCT04589845; sNCT04077463; tNCT02625961; uNCT04674683; vNCT04241185; wNCT03785249; xNCT04685135; yNCT04264702; zNCT04988295; aaNCT05595460; bbNCT03836105; ccNCT05379595; ddNCT05163028; eeNCT05306288; ffNCT0502988 |
